South Korea Insulin Drugs And Delivery Devices Market Size
| Study Period | 2021 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2021 - 2023 |
| Market Size (2025) | USD 774.08 Million |
| Market Size (2030) | USD 868.99 Million |
| CAGR (2025 - 2030) | 2.34% |
Major Players
*Disclaimer: Major Players sorted in no particular order |
South Korea Insulin Drugs And Delivery Devices Market Analysis
The South Korea Insulin Drugs And Delivery Devices Market size is estimated at USD 774.08 million in 2025, and is expected to reach USD 868.99 million by 2030, at a CAGR of 2.34% during the forecast period (2025-2030).
One of the most significant risk factors for severe COVID-19 was diabetes mellitus. This risk is believed to be influenced by several variables frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying cases of type-2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes were associated with adverse outcomes in COVID-19 patients.
Diabetes mellitus is widely prevalent and imposes a substantial socioeconomic burden on individuals and society in terms of large medical costs. It leads to complications such as cardiovascular disease. These complications are associated with increased healthcare utilization, such as having more outpatient visits, a higher probability of being hospitalized, and increased use of more medications. Therefore, complications associated with diabetes drive the escalating costs of diabetes management and their financial burden on the healthcare system.
People with type-1 diabetes cannot produce adequate insulin because their immune system attacks their insulin-producing beta cells. In contrast, people with type-2 diabetes have insulin resistance and do not make enough insulin. Diabetes patients take insulin through an injection (syringe or pen), a pump, or inhaled form. In South Korea, the prevalence of diabetes in adults is higher, and the economic burden of diabetes is higher than that of overall cancer. It is expected that increased information regarding both the magnitude and the specific components of the economic burden of diabetes in Korea will influence health policymakers to prioritize its prevention and management and to allocate more healthcare resources to diabetes to boost the insulin market's growth.
South Korea Insulin Drugs And Delivery Devices Market Trends
Rising diabetes prevalence is likely to boost the market studied over the forecast period.
In South Korea, Diabetes Population is expected to increase, registering a CAGR greater than 0.57% over the forecast period.
According to Mordor Intelligence, the Type-1 diabetes population in South Korea in the current year is 0.16 million. Effective strategies are needed to manage patients with diabetic complications. With increasing obesity, especially in childhood, decreased physical activity, and improved longevity, diabetes and prediabetes are expected to increase. When diabetes is undetected or inadequately treated, people risk serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation, leading to a greater need for access to care.
Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.
The National Health Insurance (NHI) Act covers all public health insurance in Korea. This Act covers the entire population, and all citizens earning an income in Korea must contribute a percentage of their monthly salary. Employers are also responsible for matching employee contributions. There are two health insurance agencies under the MOHW: the Health Insurance Review Agency (HIRA) and the National Health Insurance Corporation (NHIC). In particular, the HIRA is responsible for reviewing reimbursement coverage/non-coverage and pricing applications from pharmaceutical and medical device companies. The company may expand its market and obtain a larger sales volume if reimbursement is obtained.
Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to grow over the analysis period.
The Insulin Pumps Segment is expected to witness the highest growth rate over the forecast period
An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.
Insulin Pump is expected to register a CAGR of more than 3.9% in the market over the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type-1 diabetes people.
Pumps are a validated, time-tested therapeutic option in type-1 diabetes at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The Ministry of Food and Drug Safety, South Korea's medical device market regulator, plans to roll out several amendments to the country's Medical Devices Act and has expanded its list of devices eligible for electronic indications. Penetration of diabetes devices in the South Korean market supports local clinical research organizations in their clinical research trials and ensures ease of maintenance, facilitating the discovery process.
The use of continuous subcutaneous insulin infusion and continuous glucose monitoring systems has improved patient care and quality of life and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting; such advantages are likely to drive segment growth during the forecast period.
South Korea Insulin Drugs And Delivery Devices Industry Overview
The South Korean Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Recently, mergers and acquisitions between the players have helped the companies strengthen their market presence.
South Korea Insulin Drugs And Delivery Devices Market Leaders
-
Novo Nordisk
-
Eli Lilly
-
Sanofi
-
Medtronic
-
Becton Dickinson
- *Disclaimer: Major Players sorted in no particular order
South Korea Insulin Drugs And Delivery Devices Market News
- July 2023: Dongkook Pharmaceutical launched its insulin glargine biosimilar product, Glargia in South Korea. The biosimilar comes in a prefilled pen and is administered once daily.
- May 2023: Medtronic entered into a set of definitive agreements to acquire EOFlow Co. Ltd, manufacturer of the EOPatch device a tubeless, wearable, and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes.
South Korea Insulin Drugs And Delivery Devices Industry Segmentation
Insulin drugs are prescription drugs that contain insulin and treat diabetes mellitus using an insulin pump, smart pen, syringe, or other devices. The South Korea Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD) and volume (in mL) for insulin drugs and (in units) for the devices for the above segments.
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) | |
| Levemir (Insulin Detemir) | |||
| Toujeo (Insulin Glargine) | |||
| Tresiba (Insulin Degludec) | |||
| Basaglar (Insulin Glargine) | |||
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) | ||
| Humalog (Insulin lispro) | |||
| Apidra (Insulin glulisine) | |||
| FIASP (Insulin aspart) | |||
| Admelog (Insulin lispro Sanofi) | |||
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard | ||
| Humulin | |||
| Insuman | |||
| Combination Insulins | NovoMix (Biphasic Insulin aspart) | ||
| Ryzodeg (Insulin degludec and Insulin aspart) | |||
| Xultophy (Insulin degludec and Liraglutide) | |||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | |||
| Biosimilar Insulins | Insulin Glargine Biosimilars | ||
| Human Insulin Biosimilars | |||
| Device | Insulin Pumps | Insulin Pump Devices | |
| Insulin Pump Reservoirs | |||
| Insulin Infusion sets | |||
| Insulin Pens | Cartridges in reusable pens | ||
| Disposable insulin pens | |||
| Insulin Syringes | |||
| Insulin Jet Injectors | |||
| Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |
| Toujeo (Insulin Glargine) | |
| Tresiba (Insulin Degludec) | |
| Basaglar (Insulin Glargine) | |
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) |
| Humalog (Insulin lispro) | |
| Apidra (Insulin glulisine) | |
| FIASP (Insulin aspart) | |
| Admelog (Insulin lispro Sanofi) | |
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard |
| Humulin | |
| Insuman | |
| Combination Insulins | NovoMix (Biphasic Insulin aspart) |
| Ryzodeg (Insulin degludec and Insulin aspart) | |
| Xultophy (Insulin degludec and Liraglutide) | |
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | |
| Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars |
| Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | |
| Insulin Infusion sets | |
| Insulin Pens | Cartridges in reusable pens |
| Disposable insulin pens | |
| Insulin Syringes | |
| Insulin Jet Injectors |
South Korea Insulin Drugs And Delivery Devices Market Research Faqs
How big is the South Korea Insulin Drugs And Delivery Devices Market?
The South Korea Insulin Drugs And Delivery Devices Market size is expected to reach USD 774.08 million in 2025 and grow at a CAGR of 2.34% to reach USD 868.99 million by 2030.
What is the current South Korea Insulin Drugs And Delivery Devices Market size?
In 2025, the South Korea Insulin Drugs And Delivery Devices Market size is expected to reach USD 774.08 million.
Who are the key players in South Korea Insulin Drugs And Delivery Devices Market?
Novo Nordisk, Eli Lilly, Sanofi, Medtronic and Becton Dickinson are the major companies operating in the South Korea Insulin Drugs And Delivery Devices Market.
What years does this South Korea Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2024?
In 2024, the South Korea Insulin Drugs And Delivery Devices Market size was estimated at USD 755.97 million. The report covers the South Korea Insulin Drugs And Delivery Devices Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the South Korea Insulin Drugs And Delivery Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on: February 8, 2024
Our Best Selling Reports
South Korea Insulin Drugs And Delivery Devices Industry Report
Statistics for the 2025 South Korea Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. South Korea Insulin Drugs And Delivery Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
